Trilaciclib plus standard therapy for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called Trilaciclib added to standard cancer immunotherapy and chemotherapy for people with recurrent or metastatic head and neck squamous cell carcinoma that cannot be treated with surgery or radiation. The goal is to see if adding Trilaciclib helps protect the body's blood cells during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have head and neck squamous cell carcinoma that is recurrent (came back) or has spread to other parts of the body, and doctors say surgery or radiation is no longer an option.
- If your cancer came back only in the head and neck (not elsewhere), you must have had radiation therapy at least 6 months ago.
- Your blood counts (red cells, white cells, platelets) are within a healthy range.
- Your kidneys and liver are working well (based on recent blood tests).
- You are in generally good health (able to be up and about, not bedridden).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called trilaciclib to see if it can protect your blood cell counts during treatment for head and neck cancer that has come back or spread. You must not have had chemotherapy before for this stage of cancer.
This trial tests if trilaciclib can protect bone marrow during chemoradiation after surgery for advanced head and neck cancer. It is for people with specific risk factors found after surgery.
This trial tests an investigational drug called trilaciclib added to standard chemoradiation and immunotherapy for locally advanced esophageal cancer that cannot be surgically removed. The goal is to see if this combination improves treatment outcomes.
This trial tests a new drug combination for people with locally advanced triple-negative breast cancer who haven't had treatment yet. The goal is to see if adding trilaciclib to standard chemo and immunotherapy works better before surgery.
This study tests whether adding trilaciclib to a new chemotherapy (sacituzumab tirumotecan) can help people with EGFR-mutant lung cancer that keeps growing after certain targeted treatments. The goal is to see if it slows the cancer and reduces side effects.
This trial tests a drug called trilaciclib that may protect your bone marrow during chemotherapy. It is for people with several types of advanced solid tumors who will receive a specific chemo combination (paclitaxel plus carboplatin) for the first time.
Hear when a new Head & Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.